| Description | Emivirine (MKC-442) is a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. |
| In vitro | Emivirine 是一种新型非核苷类逆转录酶抑制剂，展现了针对人类免疫缺陷病毒1型（HIV-1）的强效和选择性抗病毒活性。在体内，针对实验室适应性HIV-1株的IC50值介于1.6至19 nM之间。对于临床分离株，EMV的IC50值范围是2至40 nM。对于dTTP-和dGTP依赖的DNA或RNA聚合酶活性，其Ki值分别为0.20和0.01 μM [1]。 |
| In vivo | Emivirine在体内具有强效且选择性地抗人类免疫缺陷病毒1型（HIV-1）活性。药动学特性在大鼠和猴子身上呈线性，大鼠的口服吸收率为68%。以10mg/kg的剂量口服给予大鼠Emivirine后，30分钟内可见药物在组织中的广泛分布。当口服剂量达到250 mg/kg时，大鼠的血浆和大脑中Emivirine的浓度相等[2]。 |
| Target activity | DNA polymerase activity (dTTP-dependent):0.20μM(ki), RNA polymerase activity (dGTP-dependent):0.01μM(ki) |
| Synonyms | MKC442, MKC-442, MKC 442, DRG-0302, DRG 0302, DRG0302 |
| molecular weight | 302.37 |
| Molecular formula | C17H22N2O3 |
| CAS | 149950-60-7 |
| Storage | |Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 4.8 mg/mL (15.87 mM) |
| References | 1. Panita Decha, et al. Theoretical studies on the molecular basis of HIV-1RT/NNRTIs interactions. J Enzyme Inhib Med Chem. 2011 Feb;26(1):29-36. 2. Szczech GM, et al. Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000 Jan;44(1):123-30. 3. Boudet N, Knochel P. Chemo- and regioselective functionalization of uracil derivatives. Applications to the synthesis of oxypurinol and emivirine. Org Lett. 2006 Aug 17;8(17):3737-40. PubMed PMID: 16898805. 4. Petersen L, Jørgensen PT, Nielsen C, Hansen TH, Nielsen J, Pedersen EB. Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach. J Med Chem. 2005 Feb 24;48(4):1211-20. PubMed PMID: 15715487. |